Lipopolysaccharide-binding protein plasma levels as a biomarker of obesity-related insulin resistance in adolescents.
10.3345/kjp.2016.59.5.231
- Author:
Ki Eun KIM
1
;
Young Sun CHO
;
Kyung Suk BAEK
;
Lan LI
;
Kwang Hyun BAEK
;
Jung Hyun KIM
;
Ho Seong KIM
;
Youn Ho SHEEN
Author Information
1. Department of Pediatrics, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea. epirubicin13@gmail.com
- Publication Type:Original Article
- Keywords:
Lipopolysaccharide-binding protein;
Body mass index;
Insulin resistance;
Adolescent;
Obesity
- MeSH:
Acute-Phase Proteins;
Adolescent*;
Alanine Transaminase;
Aspartate Aminotransferases;
Biomarkers;
Blood Pressure;
Body Mass Index;
Cholesterol;
Enzyme-Linked Immunosorbent Assay;
Fasting;
Glucose;
Humans;
Insulin Resistance*;
Insulin*;
Linear Models;
Liver;
Obesity;
Plasma*
- From:Korean Journal of Pediatrics
2016;59(5):231-238
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Lipopolysaccharide-binding protein (LBP) is a 65-kDa acute phase protein, derived from the liver, which is present in high concentrations in plasma. Data regarding the association between circulating plasma LBP levels and obesity-related biomarkers in the pediatric population are scarce. We aimed to determine whether there was a difference in plasma LBP levels between overweight/obese and normal-weight adolescents and to assess the correlation of circulating LBP levels with anthropometric measures and obesity-related biomarkers, including insulin resistance, liver enzyme levels, and lipid profiles. METHODS: The study included 87 adolescents aged 12-13 years; 44 were overweight/obese and 43 were of normal-weight. We assessed anthropometric and laboratory measures, including body mass index (BMI), blood pressure, insulin resistance, liver enzyme levels, and lipid profiles. Plasma LBP levels were measured using an enzyme-linked immunosorbent assay. RESULTS: The mean age of the participants was 12.9±0.3 years. Circulating plasma LBP levels were significantly increased in overweight/obese participants compared with those in normal-weight participants (7.8±1.9 µg/mL vs. 6.0±1.6 µg/mL, P<0.001). LBP levels were significantly and positively associated with BMI, systolic blood pressure, aspartate aminotransferase, alanine aminotransferase, total cholesterol, low density lipoprotein-cholesterol, fasting glucose and insulin, and insulin resistance as indicated by the homeostatic model assessment of insulin resistance (HOMA-IR) (all P<0.05). In multivariate linear regression analysis, BMI and HOMA-IR were independently and positively associated with plasma LBP levels. CONCLUSION: LBP is an inflammatory biomarker associated with BMI and obesity-related insulin resistance in adolescents. The positive correlation between these parameters suggests a potentially relevant pathophysiological mechanism linking LBP to obesity-related insulin resistance in adolescents.
